70
Participants
Start Date
June 30, 2015
Primary Completion Date
September 14, 2017
Study Completion Date
September 14, 2017
QR-010
Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
Placebo
Normal Saline
Charité Universitätsmedizin Berlin, Berlin
Motol University Hospital, Prague
Penn State Milton S. Hershey Medical Center, Hershey
Medical University of South Carolina, Charleston
Medizinische Hochschule Hannover, Hanover
Azienda Ospedaliera Universitaria Integrata di Verona, Verona
HGRL Chu Nantes, Nantes
Northwestern University, Chicago
University of Kansas Medical Center Research Institute, Kansas City
Nationwide Children's Hospital, Columbus
University of Texas Southwestern Medical Center, Dallas
Hopital Necker- Enfants Malades, Paris
Munich U. Hospital, Cystic Fibrosis Center for Adults, Munich
University of Southern California USC - Keck School of Medicine, Los Angeles
Stanford University, Palo Alto
Massachusetts General Hospital, Boston
Boston Children's Hospital, Boston
Washington University School of Medicine, St Louis
University of Washington Medical Center, Seattle
Universitair Ziekenhuis Brussel, Brussels
University of Leuven, Leuven
University of Calgary (Health Sciences Centre), Calgary
Cystic Fibrosis Center Rigshospitalet, Copenhagen
Hospital Vall D'Hebron, Barcelona
Celerion, Belfast
Royal Brompton Hospital, London
Southampton General Hospital, Southampton
Lead Sponsor
European Commission
OTHER
ProQR Therapeutics
INDUSTRY